Novartis: new positive data for Cosentyx
(CercleFinance.com) - Novartis announces new positive data in its Phase III Prevent trial, evaluating the efficacy and safety of Cosentyx (secukinumab) in patients with non-radiographic axial spondylitis (nr-axSpA).
The trial achieved its primary endpoint by showing, after 52 weeks, a clinically significant reduction in disease activity compared to placebo. It also demonstrated a sustained response and safety profile consistent with previous clinical trials.
This data adds to five years of clinical data supporting Cosentyx's long-term efficacy and safety in ankylosing spondylitis, psoriatic arthritis and psoriasis, Novartis said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.